unknown
Stage
2021
Founded
4
Investors
About
Be Biopharma develops engineered B cells as a new category of cellular medicines to unlock the potential of cell therapies beyond cytotoxicity for applications in tumors and chronic inflammatory diseases.
Explore Be Biopharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.